lasmiditan-succinate

Description: Lasmiditan succinate (COL-144, LY-573144) is a novel and selective 5-HT(1F) receptor agonist with Ki of 2.1 nM versus Ki of 1043 nM and 1357 nM at the 5-HT(1B) and 5-HT(1D) receptors, respectively. For the understanding of migraine pathophysiology, it is very important to note that a selective 5-HT(1F) receptor agonist like lasmiditan is effective in the acute treatment of migraine. Thus, migraine can be treated with a drug that has no vasoconstrictor ability. While lasmiditan most likely is effective in the treatment of migraine attacks it had, unfortunately, a high incidence of CNS related AEs in the oral RCT. If confirmed in larger studies in phase III, this might adversely limit the use of this highly specific non-vascular acute treatment of migraine. Larger studies including the parameters of patients' preferences are necessary to accurately position this new treatment principle in relation to the triptans.

References: Cephalalgia. 2010 Oct; 30(10):1159-69; J Headache Pain. 2012 Jun; 13(4):271-5.

Related CAS#: 613677-28-4 (Lasmiditan HCl); 439239-92-6 (Lasmiditan hemisuccinate); 439239-90-4 (free base)